Researchers at Sweden’s Uppsala University have designed new antibodies that may provide more effective treatments for Alzheimer’s disease. By designing antibodies that bind to even small clumps, or clumps, of the amyloid beta protein, it may be possible to check the disease’s progression.
According to a website report, time now news Developing effective treatment methods for Alzheimer’s disease has proven difficult. The most effective, which have just been approved, provide only marginal effects. There are several main reasons for their ineffectiveness, one of which is that the antibodies used do not bind to all kinds of toxic agglomerates that cause Alzheimer’s disease..
In Alzheimer’s disease, the amyloid beta protein begins to form clumps. This process called aggregation, and the created clumps are called aggregations. The research group previously showed that treatment with somatostatin peptide causes the body to begin breaking down the building blocks of Alzheimer’s.
In the new study, the results of the study were published in the journal Translational Neurodegeneration The researchers used an antibody that can bind to toxic aggregates to prevent them from harming cells. The problem with treatments currently being tested in inpatient studies is that the antibodies bind much more strongly to large masses and hardly bind to small masses at all.
Small blocks are as toxic as large blocks and many believe they are more dangerous because they can move more.
The purpose of the current study was to develop an antibody form that can bind to both large and small clumps of amyloid-beta.
The effects of the antibodies were also tested in a cell culture experiment, which showed that the new antibody form could rescue cells from death caused by amyloid-beta clumps. Although preclinical trials were not included, the team believes their results indicate that the new antibody design It can be more effective than those that have been tried so far.